Although commonly thought of as a “male” hormone, testosterone is essential for women too—it contributes to libido, sexual ...

Cindy Eckert first learned about hypoactive sexual desire disorder (HSDD)—the most common type of sexual dysfunction in women—while attending a conference as a cofounder of Slate Pharmaceuticals, a ...

In the often unspoken world of female sexual health, a revolution has started, and it began with the introduction of a unique medication called Addyi. Traditionally, when we think of sexual ...

The FDA finally approved Addyi, the controversial drug known as the female Viagra, for the treatment of flagging sexual desire in women. Efforts to make such a drug available to women have been ...

In 2013, the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) was published with a major revision to the sexual dysfunction categories, and the diagnosis of female ...

Bremelanotide significantly increased sexual desire for up to 24 hours post administration The important findings in the double-blinded, placebo controlled, crossover study showed that bremelanotide ...

Current guidelines recommend transdermal delivery of testosterone for post-menopausal women seeking treatment for hypoactive sexual desire disorder. Medherant’s TEPI patch has been developed to fill ...

There was a time when Wendy and her husband had sex three times a week. But for the past six years, the purple negligee that Wendy used to entice her husband has been stuffed in the back of a drawer.

NEW YORK (Reuters Health) - The antidepressant bupropion may hold promise for improving symptoms in younger women diagnosed with so-called hypoactive sexual desire disorder, a small study suggests.

Palatin Technologies, Inc. (NYSE MKT: PTN) is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs ...